Taken together, our results indicated that CTHRC1 can be a potential diagnostic and prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), Lung adenocarcinoma (LUAD), stomach adenocarcinoma (STAD), and Uterine corpus endometrial carcinoma (UCEC). Here, CTHRC1 is linked to lung adenocarcinoma.